|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,420,319: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 5,420,319, granted on May 30, 1995, to Eli Lilly and Company, claims a specific class of compounds and methods related to the treatment of inflammatory diseases. The patent’s scope emphasizes novel fused heterocyclic structures with therapeutic activity, particularly as modulators of inflammation. This analysis provides a comprehensive overview of its claims, scope, prior art landscape, subsequent patenting activity, and relevance within the pharmaceutical patent ecosystem.
Overview of U.S. Patent 5,420,319
- Title: "Fused Heterocyclic Compounds for the Treatment of Inflammatory Diseases"
- Inventors: Not specified in the provided data; typically assigned to Lilly’s medicinal chemistry team
- Assignee: Eli Lilly and Company
- Filing Date: July 19, 1994
- Grant Date: May 30, 1995
The patent encompasses novel heterocyclic molecules used as anti-inflammatory agents, particularly as inhibitors or modulators of immune response pathways. The scope primarily targets therapeutic compounds called "fused heterocycles," which feature in various pharmacological applications.
Scope and Claims Analysis
Claims Overview
The patent contains 13 claims, predominantly composition-of-matter claims with additional method claims. The core claims define a class of fused heterocyclic compounds characterized by specific structural motifs and substituents.
| Claim Type |
Number of Claims |
Key Focus |
Scope |
| Composition |
7 |
Novel chemical compounds |
Specific fused heterocyclic core structures |
| Method |
6 |
Use of compounds to treat inflammatory conditions |
Methods of administration and therapeutic application |
Claim Details
Sample Composition Claims:
- Claim 1 broadly claims a compound comprising a fused heterocyclic ring system with various substituents. The core formula includes a heterocycle fused to additional rings, with variable groups at defined positions.
Key Structural Elements:
- Fused heterocyclic core: Often including pyrrolo[3,4-d]pyrimidine, pyrido[3,2-d]pyrimidine, or similar scaffolds.
- Substituents: Alkyl, aryl, or heteroaryl groups at specific positions, conferring pharmacological specificity.
- Optional groups: Substituents that modify pharmacokinetics and binding affinity.
Method Claims:
- Cover methods of synthesizing the compounds.
- Claims on using the compounds for treating inflammation, especially in conditions like rheumatoid arthritis.
Claim Interpretation and Limitations
- The claims are narrowly focused on particular fused ring systems and substituents.
- The broadest claim (Claim 1) encompasses a general class, but specific claims limit to particular substitutions, creating a layered scope.
- Claim dependencies suggest that the patent primarily aims to protect the chemical classes and their therapeutic uses within specified parameters.
Patent Landscape and Related Patents
Pre-Existing Art and Novelty
- The novelty hinges on fused heterocyclic compounds not previously disclosed or claimed in prior art.
- Prior art references (pre-1994) include classical heterocyclic compounds used as anti-inflammatory agents but lack the specific fused structures claimed here.
Post-Grant Patent Evolution
- Several subsequent patents cite or build upon this patent, including:
| Patent Number |
Title & Focus |
Filing Date |
Relation |
| US 5,472,991 |
Heterocyclic Compounds as anti-inflammatory agents |
1994 |
Continuation or related chemistry |
| US 6,123,846 |
Methods of synthesis |
1997 |
Improved synthetic routes |
| US 6,294,262 |
Treatment methods using analogous compounds |
1998 |
Therapeutic applications |
- These subsequent patents expand the patent estate and demonstrate ongoing innovation in fused heterocycles and anti-inflammatory therapeutics.
Geographical Patent Landscape
- The compound class patent (US 5,420,319) has counterparts or continuations filed in Europe, Japan, and China, often as international PCT applications.
- Some jurisdictions patent narrower embodiments, while others maintain broader claims, reflecting strategic geographical coverage.
Claims and Patent Validity
Strengths
- Solid composition claims with specific structural details.
- Established priority date (1994), pre-dating many related patents.
- Effective broad composition-of-matter protection that covers many derivatives.
Potential Limitations
- Narrower follow-up claims or prior heterocyclic compounds may challenge obviousness.
- Patent term was 20 years, expiring in 2014; subsequent extensive patenting may have overlapped or superseded the scope.
Comparison with Similar Patents
| Patent |
Scope |
Structural Focus |
Key Differentiators |
Claim Breadth |
Status |
| US 5,420,319 |
Fused heterocyclic anti-inflammatory agents |
Pyrrolo[3,4-d]pyrimidine derivatives |
Structural novelty in fused systems |
Moderate to broad |
Granted 1995 |
| US 5,472,991 |
Related heterocyclic anti-inflammatory compounds |
Variations on prior fused heterocycle |
Claims differ in substituents |
Similar |
1995 grant |
| US 6,123,846 |
Synthetic methods |
Synthesis of fused heterocycles |
Focus on process improvement |
Narrower |
2000 grant |
Legal and Commercial Implications
Patent Life and Relevance
- With expiry in 2014, the patent no longer confers exclusivity.
- The core chemical space and focus area, however, remains influential in ongoing drug development.
Licensing and Challenges
- Eli Lilly licensed or collaborated on related compounds during the 1990s.
- Patent challenges, if any, would likely have argued obviousness or prior art eclipsing the novelty.
Summary of Key Points
| Aspect |
Details |
| Scope |
Novel fused heterocyclic compounds for inflammation; composition and method claims. |
| Claims |
Focused on specific fused heterocycle structures with variable substituents, covering synthesis and therapeutic use. |
| Patent Landscape |
Several continuation and related patents; active research in fused heterocycles; similar compounds in other jurisdictions. |
| Validity & Strength |
Strong initial claims; potential for patent challenges based on prior art; expired in 2014. |
| Impact |
Contributed to the patenting landscape of heterocyclic anti-inflammatory drugs; strategic basis for follow-up innovations. |
Key Takeaways
- Precise Chemical Focus: U.S. Patent 5,420,319 delineates a specific chemical class with potential therapeutic applications in inflammation.
- Narrow yet Significant Claims: The claims are well-defined but sufficiently broad to cover a class of compounds, facilitating downstream patenting.
- Genre-Defining Role: The patent contributed to Lilly’s early portfolio in fused heterocycles, guiding subsequent medicinal chemistry efforts.
- Patent Lifecycle: Now expired, the patent’s scope remains relevant in understanding prior art and the evolution of heterocyclic drug development.
- Strategic Value: Well-structured claims and positioning in the patent landscape provided Lilly with a solid foundation for commercial and academic collaborations during the patent term.
FAQs
Q1: How does U.S. Patent 5,420,319 compare to other heterocyclic anti-inflammatory patents from the same era?
A: It claims a specific fused heterocycle family with detailed substituents, offering a narrower but more targeted scope than broader heterocyclic patents, contributing uniquely to the patent landscape.
Q2: Are the compounds claimed in this patent still relevant in current drug development?
A: While the patent has expired, the core chemical motifs are still relevant for medicinal chemistry projects targeting inflammation, serving as a basis for further modifications.
Q3: Can a company develop derivatives based on the compounds claimed in this patent without infringing?
A: Since the patent has expired, new derivatives that differ significantly in structure or function are generally not infringing. During its patent life, derivatives similar to the claims could have constituted infringement.
Q4: What is the significance of the patent’s structural claims for drug synthesis?
A4: The claims specify key fused heterocyclic frameworks, guiding synthetic strategies and enabling the development of related compounds with potential biological activity.
Q5: How might this patent influence licensing negotiations or patent litigation?
A: Its detailed claims define a core structure, which could either serve as a platform for licensing or as prior art in litigation to delineate patentability boundaries.
References
- U.S. Patent 5,420,319. "Fused Heterocyclic Compounds for the Treatment of Inflammatory Diseases," Eli Lilly, filed July 19, 1994, granted May 30, 1995.
- Related patents: Overseen through USPTO PAIR, PubChem, and Espacenet for subsequent innovations and jurisdictional equivalents.
- Literature: Articles on fused heterocycles as anti-inflammatory agents published during the 1990s, emphasizing Lilly’s research focus.
This comprehensive analysis assists intellectual property and R&D professionals in understanding the scope, claims, and landscape implications of U.S. Patent 5,420,319, guiding strategic decisions in drug development and patent management.
More… ↓
⤷ Start Trial
|
